University Distinguished ProfessorNortheastern University's D'Amore-McKim School of Business
Business, Global Development, Emerging Markets, global business strategy, Developing Economies, Developing Countries, Innovation, China, India
Professor Ramamurti does research and consulting on strategy and innovation in emerging economies. His earlier work also focused on business-government relations in emerging economies. He has published several articles and books on multinationals from emerging markets and on the topic of “reverse innovation.” He teaches courses on the global business environment and global strategy, and electives on Competing in Emerging Markets. Awards & Recognition Honored as “The most outstanding thought leader on strategy and innovation in Emerging Markets in the world in 2017,” by Global Awards 2017, London (Nov 2017) Winner, 2017 Best Paper in Global Strategy Journal Award, Strategic Management Society (at SMS annual meeting in Houston, October 31, 2017) Elected Fellow, Academy of International Business, 2008
Director of the Center for Global Health Science and Security at Georgetown University Medical Center. For more than a decade, Katz has worked to help design systems and implement policies to facilitate a coordinated response to potential microbial outbreaks and pandemics in 22 countries — many low-resourced and developing. She is an expert on the World Health Organization an its International Health Regulations, and can comment on the international response to situtions like Ebola.
Renée Bukovchik Van Vechten, Ph.D., specializes in California and legislative politics and teaches courses in U.S. national institutions and public policy. She infuses her courses—such as Cal Politics, U.S. Congress, and the U.S. Presidency—with active learning elements. She the author of California Politics: A Primer, now in its 5th edition (Sage/CQ Press). Current projects involve developing a Food Politics textbook and an edited volume on internships in the discipline. Dr. Van Vechten is the recipient of multiple grants and awards for teaching, and is deeply engaged in the scholarship of teaching and learning. She organizes teaching and learning events for WPSA and co-convened the first “Teaching & Learning Conference within a Conference” at APSA in 2018. She also serves on the Rogers Smith Presidential Task Force (2018-2020), and is a Council member of APSA, the American Political Science Association (for which she chairs the Teaching & Learning Policy Committee and sits on the Executive Board, 2017-19). She is an executive board member of Pi Sigma Alpha honor society, and frequently contributes to local and national political reports. Click the tabs below for more information.
Professor of Political Science / SociologyBinghamton University, State University of New York
Sociology, Islam, islamic law, Conflict Resolution, Democratization, Politics
Associate Professor of PsychologyBinghamton University, State University of New York
Psychology, Relationships, Sexual Satisfaction, Partner Violence
Mattson’s research interests include improving the conceptualization and assessment of satisfaction in relationships and exploring the causes and consequences of functional versus dysfunctional relationship communication, including social support and intimate partner violence, respectively. His present focus is on how the effects of genetic, neuroendocrinological and early environmental factors, moderate the role of partner social support in buffering the negative impact of stress on health.
Sociology, Popular Culture, Political, War, Terrorism, Fiscal Crisis
Richard Lachmann is the author of "First Class Passengers on a Sinking Ship: Elite Politics and the Decline of Great Powers" (Verso 2020), which examines the decline of dominant economic and military powers in early modern Europe and the contemporary United States. He also is the author of "States and Power" (Polity 2010) and "What Is Historical Sociology?" (Polity 2013). He currently is researching media coverage and governmental commemoration of war deaths in the United States and Israel from the 1960s to the present.
Dr. Robert Lanford, PhD, is currently the Director of the Southwest National Primate Research Center, one of seven NIH National Primate Research Centers. He is a Scientist at the Texas Biomedical Research Institute and an Adjunct Professor at the University of Texas Health Science Center. Dr. Robert E. Lanford received a B.S. degree from the University of Texas at Arlington in 1974 and a Ph.D. in Virology from Baylor College of Medicine in 1979. He served as Assistant Professor at Baylor College of Medicine until 1984 when he moved to the Southwest Foundation for Biomedical Research (now Texas Biomedical Research Institute) to initiate programs on the use of nonhuman primates as models for human hepatitis infections. Dr. Lanford has published over 170 scientific papers and serves as a reviewer for several journals. His laboratory performs research on multiple hepatitis viruses HAV, HBV, HCV and GBV-B. One of the primary goals of his research program is to better understand the interactions of the virus with the host, and how these interactions influence either viral clearance or persistence and disease progression. His studies in the chimpanzee were the first to use total genome microarray analysis to examine viral-host interactions and the innate immune response to HCV. In collaboration with pharmaceutical companies, he has utilized the chimpanzee model of chronic HBV and HCV infections to evaluate efficacy of new antiviral therapies as the last preclinical step prior to human clinical trials. These studies contributed to the development of cocktails of antivirals that can now cure HCV infection in 12 weeks. Recently, Dr. Lanford has developed a primate model for liver cancer by the genetic engineering of primary baboon hepatocytes with activated baboon oncogenes and autologous transplantation of the cells to the liver of the immunocompetent hepatocyte donor. Efforts are ongoing in his laboratory to develop new nonhuman primate models for HBV research.
Recker is perhaps best known for a study in which he, molecular geneticist Mark Johnson and several others found a gene mutation causing bones to be twice as massive as “normal” bones. Using the genetic material from these “super bones” that were discovered virtually by accident in a Nebraska-based family, the two have been working on what some might call “nature’s cure” for osteoporosis.
Adolescent Medicine ExpertAnn and Robert H. Lurie Children's Hospital of Chicago
Lgbt, transgender children, Adolescent Medicine, Sexuality, HIV
Robert Garofalo, MD, MPH, is the Division Head of Adolescent Medicine at Ann & Robert H. Lurie Children’s Hospital of Chicago and a Professor of Pediatrics at Northwestern University Feinberg School of Medicine. He is a Co-Director of Lurie Children’s Gender and Sex Development Program, the first comprehensive program for gender nonconforming children and adolescents in the Midwest. Dr. Garofalo also directs Lurie Children’s Adolescent/Young Adult HIV Program and the Center for Gender, Sexuality and HIV Prevention, which conducts research on topics in adolescent sexual health, gender, sexuality, HIV prevention and health disparities affecting adolescent and young adult populations at risk of acquiring HIV. He is a national expert on lesbian, gay, bisexual and transgender (LGBT) health issues in youth, as well as adolescent sexuality and HIV clinical care and prevention. Dr. Garofalo is the former President of the Gay and Lesbian Medical Association. In 2010, he served as a committee member for the National Academy of Sciences/Institute of Medicine Committee on Lesbian, Gay, Bisexual and Transgender Health Issues and Research Gaps and Opportunities.
Robert Paine III, M.D. is an experienced Pulmonary and Critical Care Medicine physician who has been board-certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine. He cares for outpatients with a wide variety of pulmonary problems and has a particular interest in chronic obstructive pulmonary disease (COPD) and unexplained shortness of breath. He has a major interest in the care of critically ill patients in the medical intensive care unit (MICU) and has an ongoing research program related to the causes and treatment of acute lung injury.
Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant. EDUCATION & TRAINING MMS Harvard University, Clinical Translational Research (1997) MD Cornell University Medical College (1991) PhD Rockefeller University (1990) BS Yale University, Molecular Biophysics & Biochemistry (1984) MS Yale University, Molecular Biophysics and Biochemistry (1984) Fellowship Brigham and Women`s Hospital Fellowship Dana Farber Cancer Institute Residency Brigham and Women`s Hospital HONORS & RECOGNITION Elected to the Association of American Physicians AAP (2015) Addario Foundation Lectureship Award Bonnie Addario Foundation (2014) Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research Dana-Farber/Brigham and Women’s Cancer Center (2014) Best Doctors, New York Magazine (2014) Honorary Professor, University College London Cancer Center University College London (2012) Sikand Orator Yale University (2011) PROFESSIONAL SERVICE National Cancer Institute (2012 - Present) Thoracic Malignancy Steering Committee - National Cancer Institute
Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001. In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer. Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.
Food Allergy ExpertAnn and Robert H. Lurie Children's Hospital of Chicago
Food Allergy, Food Allergies, Asthma
Ruchi Gupta, MD, is an Attending Physician, Academic General Pediatrics and Primary Care, at Ann & Robert H. Lurie Children’s Hospital of Chicago and an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Gupta also is the Director of the Science and Outcomes of Allergy and Asthma Research Team (SOAAR). Her clinical interests are in the areas of asthma, food allergy, and eczema. She is involved in clinical, epidemiological, and community research. She has been nationally recognized for her research in the areas of food allergy and asthma epidemiology.
Director of Nutrition Services/Community OutreachAssociation of Diabetes Care & Education Specialists (ADCES)
Diabetes, Type 2 Diabetes, Diabetes Self-management, Diabetes and Adults, Diabetes and Latino, hispanic health risk factors, Hispanic Health, Bronx and Brooklyn, Latino Health, Minority Health, Minority Health and Health Equity, Health Literacy, Nutrition,
Aging, Gerontolgoy, Aging In Place, Housing, housing access, Older Adults, Nursing Home, Community Health, Occupational Therapist, health disparites, Health Policy, Nurse Practitioner, Homebound Patients, low-income communities, health care savings, Nurse,
A number of years ago, while making house calls as a nurse practitioner to homebound, low-income elderly patients in West Baltimore, Sarah Szanton noticed that their environmental challenges were often as pressing as their health challenges. Since then she has developed a program of research at the Johns Hopkins School of Nursing on the role of the environment and stressors in health disparities in older adults, particularly those trying to “age in place” or stay out of a nursing home. The result is a program called CAPABLE, which combines handyman services with nursing and occupational therapy to improve mobility, reduce disability, and decrease healthcare costs. She is currently examining the program's effectiveness through grants from the National Institutes of Health and the Innovations Office at the Center on Medicaid and Medicare Services. She is also conducting a study, funded by the Robert Wood Johnson Foundation, of whether food and energy assistance improve health outcomes for low-income older adults. A former health policy advocate, Dr. Szanton aims her research and publications toward changing policy for older adults and their families.
Sean is an assistant professor in pulmonary and critical care medicine who originally hails from the Commonwealth of Virginia. His clinical and research interests include care for patients with complex lung disease, with a focus on idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. He sees patients at the Farmington and University Hospital pulmonary clinics.
Dr. Crotty received his B.S. in Biology from the Massachusetts Institute of Technology (MIT) in 1996. He also received a B.S. in Writing from MIT the same year. Dr. Crotty undertook graduate work in virology at the University of California, San Francisco in the Program in Biological Sciences. There he discovered the mechanism of action of the antiviral drug ribavirin, widely used to treat chronic hepatitis C infections. Dr. Crotty earned his Ph.D. in Biochemistry and Molecular Biology in 2001. He then pursued postdoctoral work at the Emory University Vaccine Center with Dr. Rafi Ahmed from 2001 to 2003, studying aspects of the generation and maintenance of immune memory after viral infections. In 2003, he accepted a faculty position at LJI. The Crotty lab has helped established that follicular helper T cells (Tfh) are a distinct type of differentiated CD4 T cell uniquely specialized in B cell help, and that Tfh differentiation is controlled by the transcription factor Bcl6 (Science 2009). He has made major advances in the area of T cell help to B cells, and through this work has become an internationally recognized leader in the field of Tfh cell biology (Annual Review of Immunology 2011). Dr. Crotty was named a Pew Scholar in Biomedical Sciences in 2005, and was the recipient of the annualAmerican Association of Immunologists (AAI) Investigator Award for outstanding early-career research contributions to the field of Immunology in 2012. Dr. Crotty is also the author of Ahead of the Curve, a biography of Nobel laureate scientist David Baltimore, published in 2001, and reviewed in The Wall Street Journal, Nature, The Washington Post, The Journal of the American Medical Association (JAMA), Nature Medicine, and Discover Magazine.